review of glp-1 IUPHAR – Glucagon-like peptide-1 (GLP-1) and substance use disorders: An emerging pharmacotherapeutic target Impact of GLP-1 analogues on

MT-1 is a linear tridecapeptide preferentially activating MC1R and producing predominantly peripheral pigmentation and photoprotection biology with minimal central melanocortin receptor effects at research doses

A pre-bed dose is timed to reinforce that natural nocturnal pulse, which is why the pre-bed slot is the one most consistently kept even in a once-daily schedule

Roughly 1 in 8 (12%) consumers have taken a GLP-1 drug , per KFF, and that share is likely to rise: 26% of US consumers plan to take a weight loss drug to achieve their 2025 New Year's resolution goals , per Tebra

It is best to stick to the recommended dose of one capsule per day to avoid too much caffeine